Flexible Spending Accounts will reimburse you for incurred expenses during your FSA plan year (period of coverage).
“Incurred” refers to expenses that happen after a service or product is provided – not when you are billed or pay for the service.You cannot be reimbursed in advance for any services.
Because FSA funds are available to you on the first day of your plan year, you must be able to receive full reimbursement for your contribution.
So, if you opted in for $1,200 a year for your FSA, you could use that amount on the first day (if you wanted to).
You can submit for FSA reimbursement in two ways:
1. Your FSA Administrator might provide you with an FSA Debit Card to use toward FSA eligible expenses.
You’ll be able to use the card at approved stores or pharmacies (we accept FSA Debit Cards and all major credit cards at FSAstore.com!)
By using the FSA debit card, your expenses are auto-adjudicated (electronically approved or disapproved) from the card and you may not need to submit additional receipts to your FSA Administrator.
Some FSA Administrators could still require a receipt to substantiate a claim. Check with your FSA Administrator about reimbursement procedures for your plan.The FSA Debit Card would not be charged if something is not considered FSA eligible under your plan.
2. You’ll have to typically submit a reimbursement claims form with:
- your personal details,
- product/service details(provider information)
- amount owed
- date of service provided.
FSAstore.com can provide you with an itemized receipt after you make your order to submit to your FSA Administrator for FSA reimbursement.
Bromfenac sodium is used for the management of postoperative ocular inflammation and pain in patients who have undergone cataract extraction.
Safety and efficacy of bromfenac sodium have been evaluated in 2 randomized, double-blind, placebo-controlled studies in 527 patients who had undergone cataract surgery. In these studies, patients with a summed ocular inflammation score of 3 or higher after cataract surgery were randomized in a 2:1 ratio to receive either bromfenac 0.09% ophthalmic solution (1 drop twice daily) or vehicle for 14 days, beginning the day after surgery. At 14 days postoperatively, ocular inflammation was reduced to a level considered trace or clearing in more patients who received bromfenac (62-66%) than in those who received vehicle (40-48%). Ocular pain, tearing, foreign body sensation, and photophobia were reported in fewer patients who received bromfenac than in those who received vehicle. Among the 20% of patients who experienced ocular pain on the first day after surgery, the median time for resolution was 2 days for those treated with bromfenac compared with 4 days for those treated with vehicle.
Dosage and Administration
Bromfenac sodium is applied topically to the eye as an ophthalmic solution. Care should be taken to avoid contamination of the solution container.
Bromfenac sodium ophthalmic solution should not be administered while wearing contact lenses.
Dosage of bromfenac sodium, which is commercially available as the sesquihydrate, is expressed in terms of bromfenac.
The recommended adult dosage of bromfenac for the management of postoperative ocular inflammation and pain in patients who have undergone cataract extraction is 1 drop of a 0.09% solution in the affected eye(s) twice daily, beginning 24 hours after cataract surgery and continuing through the first 2 weeks of the postoperative period.
No special population recommendations at this time.
Known hypersensitivity to bromfenac sodium or any ingredient in the formulation.
NSAIAs may inhibit platelet aggregation and prolong bleeding time. Some reports indicate that ophthalmic NSAIAs may cause increased bleeding of ocular tissues (including hyphemas) when used in conjunction with ocular surgery. Ophthalmic NSAIAs, including bromfenac sodium, should be used with caution in patients with underlying bleeding tendencies or in those receiving drugs known to prolong bleeding time.
Cross-sensitivity may exist with aspirin, phenylacetic acid derivatives, and other NSAIAs. Bromfenac sodium ophthalmic solution should be used with caution in patients with a history of hypersensitivity to these drugs. For further discussion of cross-sensitivity of NSAIAs,
Bromfenac sodium ophthalmic solution contains sodium sulfite, which may cause allergic-type reactions (including anaphylaxis and life-threatening or less severe asthmatic episodes) in certain susceptible individuals. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low; however, such sensitivity appears to occur more frequently in asthmatic than in nonasthmatic individuals.
All topical NSAIAs may slow or delay wound healing.(See Drug Interactions: Topical Corticosteroids.)
Use of topical NSAIAs may result in keratitis. In some susceptible patients, continued use of topical NSAIAs also may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation; these events may be sight-threatening. Patients presenting with evidence of corneal epithelial breakdown should be advised to discontinue topical NSAIA therapy immediately and should be closely monitored for corneal health.
Patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for developing adverse corneal effects that may become sight-threatening. Topical NSAIAs should be used with caution in these patients.
Use of topical NSAIAs more than 24 hours prior to surgery or use beyond 14 days postoperatively may precipitate or exacerbate adverse corneal effects.
Category C. Avoid use in late pregnancy (i.e., third trimester) because of known effects on fetal cardiovascular system (possible premature closure of the ductus arteriosus).
Not known whether bromfenac is distributed into milk following topical application to the eye. Caution if used in nursing women.
Safety and efficacy not established in children younger than 18 years of age.
No substantial differences in safety and efficacy relative to younger adults.
Common Adverse Effects
Adverse effects reported in 2% or more of patients receiving bromfenac sodium ophthalmic solution include abnormal ocular sensation, conjunctival hyperemia, ocular redness or irritation (e.g., pruritus, burning, stinging, pain), headache, and iritis.
No formal drug interaction studies have been performed to date.
Potential pharmacologic interaction (increased potential for wound-healing complications). (See Wound-healing Complications under Warnings/Precautions: General Precautions, in Cautions.)